bioAffinity Technologies Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020
Revenue	2.53	0	0	0
Revenue Growth (YoY)	52627.44%	-	-	-
Cost of Revenue	1.74	0	0	0
Gross Profit	0.79	0	0	0
Selling, General & Admin	6.79	2.48	1.07	0.99
Research & Development	1.47	1.38	1.01	1.42
Other Operating Expenses	0.51	0.16	0.13	0.19
Operating Expenses	8.76	4.02	2.21	2.6
Operating Income	-7.97	-4.01	-2.21	-2.6
Interest Expense / Income	0.04	2.53	1	0.38
Other Expense / Income	-0.09	1.61	3.12	4.28
Pretax Income	-7.92	-8.15	-6.32	-7.27
Income Tax	0.02	0	0	0
Net Income	-7.94	-8.15	-6.33	-7.27
Shares Outstanding (Basic)	9	4	3	3
Shares Outstanding (Diluted)	9	4	3	3
Shares Change	94.43%	68.17%	0.01%	-
EPS (Basic)	-0.91	-1.81	-2.36	-2.73
EPS (Diluted)	-0.91	-1.81	-2.36	-2.73
Free Cash Flow	-6.06	-4.29	-2.05	-2.21
Free Cash Flow Per Share	-0.69	-0.95	-0.77	-0.83
Gross Margin	31.26%	90.28%	-	-
Operating Margin	-314.84%	-83511.51%	-	-
Profit Margin	-313.41%	-169771.25%	-	-
Free Cash Flow Margin	-239.32%	-89336.50%	-	-
EBITDA	-7.63	-5.61	-5.32	-6.86
EBITDA Margin	-301.26%	-116777.68%	-	-
Depreciation & Amortization	0.25	0.01	0	0.02
EBIT	-7.88	-5.62	-5.32	-6.88
EBIT Margin	-311.11%	-116989.67%	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).